© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, AgeX Therapeutics, Inc. (AGE) shows an Average True Range (ATR) of 2.58 and an Enterprise Value of 31.78M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into AGE's underlying financial health and market activity.
AgeX Therapeutics, Inc. (AGE) technical indicators as of December 22, 2025: the SMA 20 is -22.16%, SMA 50 at -20.62%, and SMA 200 at -44.79%. The RSI 14 value is 41.06, suggesting its current momentum. These technical analysis signals help assess AGE's price trends and potential future movements.
AgeX Therapeutics, Inc. (AGE) stock performance overview as of December 22, 2025: The 52-week high is N/A (currently -68.44% below), and the 52-week low is N/A (currently 1.81% above). Over the past year, AGE's performance is -51.56%, compared to the S&P 500's 12.87% change.
According to market data, AgeX Therapeutics, Inc. (AGE) stock's recent performance metrics show that over the last month, AGE is -14.82%, with a Year-to-Date (YTD) performance of -18.02%. Over the past year, the stock has seen a -51.56% change. These figures summarize AGE's price movements across various periods, reflecting its historical returns.
According to current financial data, AGE stock's P/E (TTM) ratio is -4.75, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for AGE, including P/S (239.30), P/B (65.21), and P/FCF (-1.18), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.